Acute pancreatitis linked to bevacizumab: A case report
Introduction: The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly being used in the treatment of malignant tumors. It is the first molecular-targeted agent used in the treatment of several ovarian cancers. The typical side effects of this drug are hypertension...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2018-08-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S245233641730105X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849396476820586496 |
|---|---|
| author | Arif Hakan Önder Banu Öztürk Ali Murat Tatlı Erkan Kayıkçıoğlu |
| author_facet | Arif Hakan Önder Banu Öztürk Ali Murat Tatlı Erkan Kayıkçıoğlu |
| author_sort | Arif Hakan Önder |
| collection | DOAJ |
| description | Introduction: The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly being used in the treatment of malignant tumors. It is the first molecular-targeted agent used in the treatment of several ovarian cancers. The typical side effects of this drug are hypertension and proteinuria. Bevacizumab-related acute pancreatitis (AP) has not been described before, but AP associated with other chemotherapeutic agents has been reported. Research has shown that patients can develop AP when taking sorafenib, a multiple tyrosine kinase inhibitor that inhibits VEGF. Case presentation: We explored the case of a 48-year-old woman who presented with undefined upper abdominal pain after receiving a cisplatin-gemcitabine-bevacizumab combination treatment as second-line therapy for metastatic ovarian cancer. Our patient was hospitalized because of AP after two cycles of this treatment. The patient started experiencing abdominal pain after the first course of chemotherapy. The severity and duration of this pain increased after the second cycle of chemotherapy. Her abdominal pain and elevated serum amylase disappeared when treated by chemotherapy without bevacizumab; this also improved her clinical pancreatitis. Conclusions: AP without other etiological factors can occur in patients treated by chemotherapy. Furthermore, bevacizumab might induce the side effects of AP. |
| format | Article |
| id | doaj-art-b94809552cee41beb65182d9d199ae82 |
| institution | Kabale University |
| issn | 2452-3364 |
| language | English |
| publishDate | 2018-08-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Journal of Oncological Sciences |
| spelling | doaj-art-b94809552cee41beb65182d9d199ae822025-08-20T03:39:19ZengGalenos Publishing HouseJournal of Oncological Sciences2452-33642018-08-014210811010.1016/j.jons.2018.03.004Acute pancreatitis linked to bevacizumab: A case reportArif Hakan Önder0Banu Öztürk1Ali Murat Tatlı2Erkan Kayıkçıoğlu3Corresponding author. Tel.: +9005052517853.; Health Sciences University Antalya Training and Research Hospital Medical Oncology Department, Antalya, TurkeyHealth Sciences University Antalya Training and Research Hospital Medical Oncology Department, Antalya, TurkeyHealth Sciences University Antalya Training and Research Hospital Medical Oncology Department, Antalya, TurkeyHealth Sciences University Antalya Training and Research Hospital Medical Oncology Department, Antalya, TurkeyIntroduction: The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly being used in the treatment of malignant tumors. It is the first molecular-targeted agent used in the treatment of several ovarian cancers. The typical side effects of this drug are hypertension and proteinuria. Bevacizumab-related acute pancreatitis (AP) has not been described before, but AP associated with other chemotherapeutic agents has been reported. Research has shown that patients can develop AP when taking sorafenib, a multiple tyrosine kinase inhibitor that inhibits VEGF. Case presentation: We explored the case of a 48-year-old woman who presented with undefined upper abdominal pain after receiving a cisplatin-gemcitabine-bevacizumab combination treatment as second-line therapy for metastatic ovarian cancer. Our patient was hospitalized because of AP after two cycles of this treatment. The patient started experiencing abdominal pain after the first course of chemotherapy. The severity and duration of this pain increased after the second cycle of chemotherapy. Her abdominal pain and elevated serum amylase disappeared when treated by chemotherapy without bevacizumab; this also improved her clinical pancreatitis. Conclusions: AP without other etiological factors can occur in patients treated by chemotherapy. Furthermore, bevacizumab might induce the side effects of AP.http://www.sciencedirect.com/science/article/pii/S245233641730105X |
| spellingShingle | Arif Hakan Önder Banu Öztürk Ali Murat Tatlı Erkan Kayıkçıoğlu Acute pancreatitis linked to bevacizumab: A case report Journal of Oncological Sciences |
| title | Acute pancreatitis linked to bevacizumab: A case report |
| title_full | Acute pancreatitis linked to bevacizumab: A case report |
| title_fullStr | Acute pancreatitis linked to bevacizumab: A case report |
| title_full_unstemmed | Acute pancreatitis linked to bevacizumab: A case report |
| title_short | Acute pancreatitis linked to bevacizumab: A case report |
| title_sort | acute pancreatitis linked to bevacizumab a case report |
| url | http://www.sciencedirect.com/science/article/pii/S245233641730105X |
| work_keys_str_mv | AT arifhakanonder acutepancreatitislinkedtobevacizumabacasereport AT banuozturk acutepancreatitislinkedtobevacizumabacasereport AT alimurattatlı acutepancreatitislinkedtobevacizumabacasereport AT erkankayıkcıoglu acutepancreatitislinkedtobevacizumabacasereport |